<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05100212</url>
  </required_header>
  <id_info>
    <org_study_id>4364</org_study_id>
    <nct_id>NCT05100212</nct_id>
  </id_info>
  <brief_title>umBilical Or Adult Donor Red Blood Cells in Extremely Low Gestational Age Neonates and Retinopathy of Prematurity (BORN)</brief_title>
  <acronym>BORN</acronym>
  <official_title>Umbilical or Adult Donor Red Blood Cells to Transfuse Extremely Low Gestational Age Neonates. A Randomized Trial to Assess the Effect on Retinopathy of Prematurity Severity.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondazione Policlinico Universitario Agostino Gemelli IRCCS</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fresenius Hemocare</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fondazione Policlinico Universitario Agostino Gemelli IRCCS</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Extremely low gestational age neonates (ELGAN, i.e., born before 28 gestation weeks) are&#xD;
      among the most heavily transfused pediatric patients. In this clinical setting, repeated red&#xD;
      blood cell (RBC) transfusions independently predict a poor outcome, with a higher risk for&#xD;
      mortality and morbidity. Recent studies from our own and other groups highlighted a close&#xD;
      association between low levels of fetal hemoglobin (HbF) and severity of retinopathy of&#xD;
      prematurity (ROP) and bronchopulmonary dysplasia (BPD), two disabilities that frequently&#xD;
      complicate preterm birth. This association is not surprising, considering that 1) preterm&#xD;
      neonates have a highly immature antioxidant reserve and both ROP and BPD rely on the&#xD;
      oxidative damage as underlying mechanism; 2) in comparison with HbA, HbF is endowed with&#xD;
      higher oxygen affinity, greater redox potential, higher tetrameric stability, and higher&#xD;
      ability to generate unbound nitric oxide, all functions potentially protective in presence of&#xD;
      an oxidative challenge; 3) in normal prenatal life, developing organ and tissues are exposed&#xD;
      exclusively to HbF until last weeks of gestation; 4) in preterm neonates, the switch of the&#xD;
      synthesis from HbF to HbA occurs around their due date, i.e., several weeks after the&#xD;
      premature birth; 5) when preterm neonates receive transfusions, their tissues are abruptly&#xD;
      exposed to high levels of HbA. We have recently run a pilot trial demonstrating as a&#xD;
      proof-of-concept that transfusing cord blood red blood cell concentrates (CB-RBC) effectively&#xD;
      prevents or restrains the HbF loss consequent to adult donor standard transfusions (A-RBC).&#xD;
      This study explores the hypothesis that transfusing CB-RBCs instead of A-RBC may lower the&#xD;
      incidence of severe ROP in ELGANs needing transfusions.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Interventional, randomized, controlled, double-blind, with an adaptive design to evaluate safety and efficacy of allogeneic CB-RBC transfusions.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Retinopathy of prematurity</measure>
    <time_frame>up to the age of 40 weeks</time_frame>
    <description>Incidence of severe ROP (stage 3 and higher) in CB-RBC and A-RBC arms</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">146</enrollment>
  <condition>Retinopathy of Prematurity</condition>
  <arm_group>
    <arm_group_label>Adult-RBC transfusions</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Adult-red blood cell concentrate transfusions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CB-RBC transfusions</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cord blood-red blood cell concentrate transfusions</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>cord blood-RBC concentrates</intervention_name>
    <description>Patients in the experimental arm are candidates to receive CB-RBC units until the completion of 31 weeks of postmenstrual age (31+6). In case of unavailability of an ABO/Rh matched CB-RBC unit, patients receive adult -RBC (standard transfusions).</description>
    <arm_group_label>CB-RBC transfusions</arm_group_label>
    <other_name>cord blood packed RBC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>adult donor RBC concentrates</intervention_name>
    <description>Patients in the comparator arm are candidates to receive adult donor-RBC units</description>
    <arm_group_label>Adult-RBC transfusions</arm_group_label>
    <other_name>adult donor packed RBC</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  gestational age (GA) at birth between 24+0 and 27+6 weeks&#xD;
&#xD;
          -  signed informed consent of parents.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        One or more of the following:&#xD;
&#xD;
          -  maternal-fetal immunization&#xD;
&#xD;
          -  hydrops fetalis&#xD;
&#xD;
          -  major congenital malformations associated or not with genetic syndromes&#xD;
&#xD;
          -  previous transfusions&#xD;
&#xD;
          -  hemorrhage at birth&#xD;
&#xD;
          -  congenital infections&#xD;
&#xD;
          -  out-born infants&#xD;
&#xD;
          -  health care team deeming it inappropriate to approach the infant's family for informed&#xD;
             consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>24 Weeks</minimum_age>
    <maximum_age>27 Weeks</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luciana Teofili, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fondazione Policlinico Gemelli IRCCS</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nicoletta Orlando, BSC</last_name>
    <phone>0630154373</phone>
    <phone_ext>39</phone_ext>
    <email>nicolettaorlando@hotmail.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fondazione Policlinico Universitario A. Gemelli IRCCS</name>
      <address>
        <city>Roma</city>
        <state>RM</state>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Luciana Teofili, MD</last_name>
      <phone>0630154373</phone>
      <phone_ext>39</phone_ext>
      <email>luciana.teofili@unicatt.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fondazione Policlinico Universitario A.Gemelli IRCCS</name>
      <address>
        <city>Rome</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>October 14, 2021</study_first_submitted>
  <study_first_submitted_qc>October 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 29, 2021</study_first_posted>
  <last_update_submitted>November 18, 2021</last_update_submitted>
  <last_update_submitted_qc>November 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Retinopathy of Prematurity</mesh_term>
    <mesh_term>Premature Birth</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

